Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates - Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; received Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate Medicare reimbursement - - Announced first patient dosed in randomized Phase 2b clinical trial evaluating ...